1 Preface
2 Scope and Methodology
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 Executive Summary
4 Introduction
4.1 Overview
4.2 Key Industry Trends
5 Global Human Insulin Market
5.1 Market Overview
5.2 Market Performance
5.3 Impact of COVID-19
5.4 Market Forecast
6 Market Breakup by Product Type
6.1 Drugs
6.1.1 Market Trends
6.1.2 Market Breakup by Type
6.1.2.1 Human Insulin Analogs and Biosimilars
6.1.2.1.1 Rapid Acting
6.1.2.1.1.1 Market Trends
6.1.2.1.1.2 Market Forecast
6.1.2.1.2 Long Acting
6.1.2.1.2.1 Market Trends
6.1.2.1.2.2 Market Forecast
6.1.2.1.3 Premixed
6.1.2.1.3.1 Market Trends
6.1.2.1.3.2 Market Forecast
6.1.2.2 Human Insulin Biologics
6.1.2.2.1 Short Acting
6.1.2.2.1.1 Market Trends
6.1.2.2.1.2 Market Forecast
6.1.2.2.2 Intermediate Acting
6.1.2.2.2.1 Market Trends
6.1.2.2.2.2 Market Forecast
6.1.2.2.3 Premixed
6.1.2.2.3.1 Market Trends
6.1.2.2.3.2 Market Forecast
6.1.3 Market Forecast
6.2 Delivery Devices
6.2.1 Market Trends
6.2.2 Market Breakup by Type
6.2.2.1 Pens
6.2.2.1.1 Reusable Pens
6.2.2.1.2 Disposable Pens
6.2.2.2 Pen Needles
6.2.2.2.1 Standard Pen Needles
6.2.2.2.2 Safety Pen Needles
6.2.2.3 Syringes
6.2.2.4 Others
6.2.3 Market Forecast
7 Market Breakup by Distribution Channel
7.1 Retail Pharmacies
7.1.1 Market Trends
7.1.2 Market Forecast
7.2 Hospital Pharmacies
7.2.1 Market Trends
7.2.2 Market Forecast
7.3 Online Retail Stores
7.3.1 Market Trends
7.3.2 Market Forecast
7.4 Others
7.4.1 Market Trends
7.4.2 Market Forecast
8 Market Breakup by Disease Type
8.1 Type I Diabetes
8.1.1 Market Trends
8.1.2 Market Forecast
8.2 Type II Diabetes
8.2.1 Market Trends
8.2.2 Market Forecast
9 Market Breakup by Region
9.1 North America
9.1.1 United States
9.1.1.1 Market Trends
9.1.1.2 Market Forecast
9.1.2 Canada
9.1.2.1 Market Trends
9.1.2.2 Market Forecast
9.2 Asia Pacific
9.2.1 China
9.2.1.1 Market Trends
9.2.1.2 Market Forecast
9.2.2 Japan
9.2.2.1 Market Trends
9.2.2.2 Market Forecast
9.2.3 India
9.2.3.1 Market Trends
9.2.3.2 Market Forecast
9.2.4 South Korea
9.2.4.1 Market Trends
9.2.4.2 Market Forecast
9.2.5 Australia
9.2.5.1 Market Trends
9.2.5.2 Market Forecast
9.2.6 Indonesia
9.2.6.1 Market Trends
9.2.6.2 Market Forecast
9.2.7 Others
9.2.7.1 Market Trends
9.2.7.2 Market Forecast
9.3 Europe
9.3.1 Germany
9.3.1.1 Market Trends
9.3.1.2 Market Forecast
9.3.2 France
9.3.2.1 Market Trends
9.3.2.2 Market Forecast
9.3.3 United Kingdom
9.3.3.1 Market Trends
9.3.3.2 Market Forecast
9.3.4 Italy
9.3.4.1 Market Trends
9.3.4.2 Market Forecast
9.3.5 Spain
9.3.5.1 Market Trends
9.3.5.2 Market Forecast
9.3.6 Russia
9.3.6.1 Market Trends
9.3.6.2 Market Forecast
9.3.7 Others
9.3.7.1 Market Trends
9.3.7.2 Market Forecast
9.4 Latin America
9.4.1 Brazil
9.4.1.1 Market Trends
9.4.1.2 Market Forecast
9.4.2 Mexico
9.4.2.1 Market Trends
9.4.2.2 Market Forecast
9.4.3 Others
9.4.3.1 Market Trends
9.4.3.2 Market Forecast
9.5 Middle East and Africa
9.5.1 Market Trends
9.5.2 Market Breakup by Country
9.5.3 Market Forecast
10 SWOT Analysis
10.1 Overview
10.2 Strengths
10.3 Weaknesses
10.4 Opportunities
10.5 Threats
11 Value Chain Analysis
12 Porters Five Forces Analysis
12.1 Overview
12.2 Bargaining Power of Buyers
12.3 Bargaining Power of Suppliers
12.4 Degree of Competition
12.5 Threat of New Entrants
12.6 Threat of Substitutes
13 Price Indicators
14 Competitive Landscape
14.1 Market Structure
14.2 Key Players
14.3 Profiles of Key Players
14.3.1 B. Braun Melsungen AG
14.3.1.1 Company Overview
14.3.1.2 Product Portfolio
14.3.1.3 SWOT Analysis
14.3.2 Becton, Dickinson and Company (BD)
14.3.2.1 Company Overview
14.3.2.2 Product Portfolio
14.3.2.3 Financials
14.3.2.4 SWOT Analysis
14.3.3 Biocon
14.3.3.1 Company Overview
14.3.3.2 Product Portfolio
14.3.3.3 Financials
14.3.3.4 SWOT Analysis
14.3.4 Eli Lilly and Company
14.3.4.1 Company Overview
14.3.4.2 Product Portfolio
14.3.4.3 Financials
14.3.4.4 SWOT Analysis
14.3.5 Gulf Pharmaceutical Industries (Julphar)
14.3.5.1 Company Overview
14.3.5.2 Product Portfolio
14.3.5.3 Financials
14.3.5.4 SWOT Analysis
14.3.6 Novo Nordisk A/S
14.3.6.1 Company Overview
14.3.6.2 Product Portfolio
14.3.6.3 Financials
14.3.6.4 SWOT Analysis
14.3.7 Pfizer Inc.
14.3.7.1 Company Overview
14.3.7.2 Product Portfolio
14.3.7.3 Financials
14.3.7.4 SWOT Analysis
14.3.8 Groupe Sanofi
14.3.8.1 Company Overview
14.3.8.2 Product Portfolio
14.3.8.3 Financials
14.3.8.4 SWOT Analysis
14.3.9 SEDICO Co.
14.3.9.1 Company Overview
14.3.9.2 Product Portfolio
14.3.10 Wockhardt Limited
14.3.10.1 Company Overview
14.3.10.2 Product Portfolio
14.3.10.3 Financials
14.3.11 Ypsomed AG
14.3.11.1 Company Overview
14.3.11.2 Product Portfolio
14.3.11.3 Financials
14.3.11.4 SWOT Analysis
❖ 免責事項 ❖
http://www.globalresearch.jp/disclaimer
